Drug Profile
Research programme: anti-cancer monocloncal antibodies - Perseus Proteomics
Alternative Names: PPMX 2017; PPZ 3124Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Perseus Proteomics
- Class Monoclonal antibodies
- Mechanism of Action AMIGO2 protein antagonists; Antibody-dependent cell cytotoxicity; Cadherin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Japan (Parenteral)